中毒症治療法の世界市場予測・分析2019-2023

◆英語タイトル:Addictions Therapeutics Market by Type and Geography - Forecast and Analysis 2019-2023
◆商品コード:IRTNTR32077
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年9月28日
◆ページ数:155
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、中毒症治療法の世界市場について調べ、中毒症治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、中毒症治療法の市場規模をセグメンテーション別(種類別(アルコール中毒治療薬、たばこ中毒治療薬、薬物中毒治療薬)、)と地域別(グローバル)に分けて算出しました。Technavio社は中毒症治療法の世界市場規模が2019-2023期間中に年平均5%成長すると予測しています。
・サマリー
・レポートの範囲
・中毒症治療法の市場状況
・中毒症治療法の市場規模
・中毒症治療法の市場予測
・中毒症治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(アルコール中毒治療薬、たばこ中毒治療薬、薬物中毒治療薬)
・中毒症治療法の顧客状況
・主要地域別市場規模:グローバル
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Addictions Therapeutics Market: About this market

Technavio’s addictions therapeutics market analysis considers sales from alcohol addiction therapeutics, tobacco addiction therapeutics, and drug addiction therapeutics type. Our analysis also considers the sales of addictions therapeutics in Asia, Europe, North America, and ROW. In 2018, the alcohol addiction therapeutics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the rise in alcohol addiction around the globe will play a significant role in the alcohol addiction therapeutics segment to maintain its market position. Also, our global addictions therapeutics market report looks at factors such as the high consumption of alcohol, tobacco, and opioid products, approval of new drugs and launch of digital therapeutics to treat addiction, and initiatives to increase awareness about and combat addiction. However, minimum insurance coverage for addiction treatment, stringent government policies and regulations, and social stigma among the drug-addicted population may hamper the growth of the addictions therapeutics industry over the forecast period.

Global Addictions Therapeutics Market: Overview

Initiatives to increase awareness about and combat addiction

There is an increase in the awareness about substance abuse and combat drug abuse due to the growing number of initiatives undertaken by federal departments and agencies. For instance, in India, drug abuse among the population is high, particularly in areas of Punjab, Haryana, and Uttar Pradesh. Therefore, the government of these states has undertaken special steps to combat drug abuse. They are providing information and resources to increase the understanding of addiction, drug and alcohol prevention, awareness about heroin/opioid epidemic, and more. Such initiatives will boost the demand for addiction therapeutics and lead to the expansion of the global addictions therapeutics market at a CAGR of over 5% during the forecast period.

Emergence of free state-run addiction treatment programs and facilities

Free treatment facilities and addiction treatment programs are available for those individuals struggling with substance use disorders who cannot otherwise afford the treatment. State-funded drug rehabilitation centers provide services such as free detox, inpatient facility stay, outpatient services, and other drug rehabilitation services. The availability of these treatment facilities is increasing the demand for addiction therapeutics. These free clinics and rehabilitation centers help people who are struggling with the physical, emotional, and financial costs of addiction. This is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global addictions therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global addictions therapeutics market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading addictions therapeutics manufacturers, that include Alkermes Plc, Amneal Pharmaceuticals Inc., Indivior Plc, Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Novo Nordisk AS, Novo Nordisk AS, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Also, the addictions therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Alcohol addiction therapeutics – Market size and forecast 2018-2023

Tobacco addiction therapeutics – Market size and forecast 2018-2023

Drug addiction therapeutics – Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 10: MARKET TRENDS

Increasing R&D of novel drugs

Emergence of free state-run addiction treatment programs and facilities

Consolidation of rehabilitation centers

PART 11: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 12: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Alkermes Plc

Amneal Pharmaceuticals Inc.

Indivior Plc

Johnson & Johnson Services Inc.

Mylan NV

Novartis AG

Novo Nordisk AS

Opiant Pharmaceuticals Inc.

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

PART 13: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 14: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Type – Market share 2018-2023 (%)

Exhibit 19: Comparison by type

Exhibit 20: Alcohol addiction therapeutics – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Alcohol addiction therapeutics – Year-over-year growth 2019-2023 (%)

Exhibit 22: Tobacco addiction therapeutics – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Tobacco addiction therapeutics – Year-over-year growth 2019-2023 (%)

Exhibit 24: Drug addiction therapeutics – Market size and forecast 2018-2023 ($ millions)

Exhibit 25: Drug addiction therapeutics – Year-over-year growth 2019-2023 (%)

Exhibit 26: Market opportunity by type

Exhibit 27: Customer landscape

Exhibit 28: Market share by geography 2018-2023 (%)

Exhibit 29: Geographic comparison

Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: North America – Year-over-year growth 2019-2023 (%)

Exhibit 32: Top 3 countries in North America

Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in Europe

Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in Asia

Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 41: Top 3 countries in ROW

Exhibit 42: Key leading countries

Exhibit 43: Market opportunity

Exhibit 44: Impact of drivers and challenges

Exhibit 45: Vendor landscape

Exhibit 46: Landscape disruption

Exhibit 47: Vendors covered

Exhibit 48: Vendor classification

Exhibit 49: Market positioning of vendors

Exhibit 50: Alkermes Plc – Vendor overview

Exhibit 51: Alkermes Plc – Business segments

Exhibit 52: Alkermes Plc – Organizational developments

Exhibit 53: Alkermes Plc – Geographic focus

Exhibit 54: Alkermes Plc – Key offerings

Exhibit 55: Alkermes Plc – Key customers

Exhibit 56: Amneal Pharmaceuticals Inc. – Vendor overview

Exhibit 57: Amneal Pharmaceuticals Inc. – Business segments

Exhibit 58: Amneal Pharmaceuticals Inc. – Organizational developments

Exhibit 59: Amneal Pharmaceuticals Inc. – Segment focus

Exhibit 60: Amneal Pharmaceuticals Inc. – Key offerings

Exhibit 61: Amneal Pharmaceuticals Inc. – Key customers

Exhibit 62: Indivior Plc – Vendor overview

Exhibit 63: Indivior Plc – Business segments

Exhibit 64: Indivior Plc – Organizational developments

Exhibit 65: Indivior Plc – Geographic focus

Exhibit 66: Indivior Plc – Key offerings

Exhibit 67: Indivior Plc – Key customers

Exhibit 68: Johnson & Johnson Services, Inc. – Vendor overview

Exhibit 69: Johnson & Johnson Services, Inc. – Business segments

Exhibit 70: Johnson & Johnson Services, Inc. – Organizational developments

Exhibit 71: Johnson & Johnson Services, Inc. – Geographic focus

Exhibit 72: Johnson & Johnson Services, Inc. – Segment focus

Exhibit 73: Johnson & Johnson Services, Inc. – Key offerings

Exhibit 74: Johnson & Johnson Services, Inc. – Key customers

Exhibit 75: Mylan NV – Vendor overview

Exhibit 76: Mylan NV – Product segments

Exhibit 77: Mylan NV – Organizational developments

Exhibit 78: Mylan NV – Geographic focus

Exhibit 79: Mylan NV – Segment focus

Exhibit 80: Mylan NV – Key offerings

Exhibit 81: Mylan NV – Key customers

Exhibit 82: Novartis AG – Vendor overview

Exhibit 83: Novartis AG – Business segments

Exhibit 84: Novartis AG – Organizational developments

Exhibit 85: Novartis AG – Geographic focus

Exhibit 86: Novartis AG – Segment focus

Exhibit 87: Novartis AG – Key offerings

Exhibit 88: Novartis AG – Key customers

Exhibit 89: Novo Nordisk AS – Vendor overview

Exhibit 90: Novo Nordisk AS – Business segments

Exhibit 91: Novo Nordisk AS – Organizational developments

Exhibit 92: Novo Nordisk AS – Geographic focus

Exhibit 93: Novo Nordisk AS – Segment focus

Exhibit 94: Novo Nordisk AS – Key offerings

Exhibit 95: Novo Nordisk AS – Key customers

Exhibit 96: Opiant Pharmaceuticals Inc. – Vendor overview

Exhibit 97: Opiant Pharmaceuticals Inc. – Business segments

Exhibit 98: Opiant Pharmaceuticals Inc. – Organizational developments

Exhibit 99: Opiant Pharmaceuticals Inc. – Key offerings

Exhibit 100: Opiant Pharmaceuticals Inc. – Key customers

Exhibit 101: Pfizer Inc. – Vendor overview

Exhibit 102: Pfizer Inc. – Business segments

Exhibit 103: Pfizer Inc. – Organizational developments

Exhibit 104: Pfizer Inc. – Geographic focus

Exhibit 105: Pfizer Inc. – Segment focus

Exhibit 106: Pfizer Inc. – Key offerings

Exhibit 107: Pfizer Inc. – Key customers

Exhibit 108: Teva Pharmaceutical Industries Ltd. – Vendor overview

Exhibit 109: Teva Pharmaceutical Industries Ltd. – Business segments

Exhibit 110: Teva Pharmaceutical Industries Ltd. – Organizational developments

Exhibit 111: Teva Pharmaceutical Industries Ltd. – Segment focus

Exhibit 112: Teva Pharmaceutical Industries Ltd. – Key offerings

Exhibit 113: Teva Pharmaceutical Industries Ltd. – Key customers

Exhibit 114: Validation techniques employed for market sizing

Exhibit 115: Definition of market positioning of vendors



【掲載企業】

Alkermes Plc, Amneal Pharmaceuticals Inc., Indivior Plc, Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Novo Nordisk AS, Opiant Pharmaceuticals Inc., Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[中毒症治療法の世界市場予測・分析2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆